BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36971689)

  • 1. Can sarcopenia predict complete response after total neoadjuvant therapy in advanced rectal cancer? A multicentre observational cohort study.
    Bedrikovetski S; Traeger L; Price TJ; Carruthers S; Selva-Nayagam S; Moore JW; Sammour T
    J Surg Oncol; 2023 Jul; 128(1):75-84. PubMed ID: 36971689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of sarcopenia on pathologic complete response following neoadjuvant chemoradiation in rectal cancer.
    Olmez T; Ofluoglu CB; Sert OZ; Keser SH; Gulmez S; Senger AS; Uzun O; Duman M; Polat E
    Langenbecks Arch Surg; 2020 Dec; 405(8):1131-1138. PubMed ID: 32902708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 4. Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy.
    Takeda Y; Akiyoshi T; Matsueda K; Fukuoka H; Ogura A; Miki H; Hiyoshi Y; Nagasaki T; Konishi T; Fujimoto Y; Fukunaga Y; Ueno M
    PLoS One; 2018; 13(4):e0195406. PubMed ID: 29630652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 6. Association Between RAS/BRAF Mutations and Complete Response Following Total Neoadjuvant Therapy in Patients with Rectal Cancer: A Prospective Multicentered Study.
    Bedrikovetski S; Traeger L; Fitzsimmons T; Price TJ; Ruszkiewicz AR; Vather R; Sammour T
    Ann Surg Oncol; 2024 Mar; 31(3):1681-1689. PubMed ID: 38071720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenia assessed by skeletal muscle mass volume is a prognostic factor for oncological outcomes of rectal cancer patients undergoing neoadjuvant chemoradiotherapy followed by surgery.
    Horie K; Matsuda T; Yamashita K; Hasegawa H; Utsumi M; Urakawa N; Kanaji S; Oshikiri T; Kakeji Y
    Eur J Surg Oncol; 2022 Apr; 48(4):850-856. PubMed ID: 34756762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative sarcopenia is a poor prognostic factor in lower rectal cancer patients undergoing neoadjuvant chemoradiotherapy: a retrospective study.
    Abe S; Kawai K; Nozawa H; Sasaki K; Murono K; Emoto S; Kishikawa J; Ishii H; Yokoyama Y; Nagai Y; Anzai H; Sonoda H; Oba K; Ishihara S
    Int J Clin Oncol; 2022 Jan; 27(1):141-153. PubMed ID: 34741193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 10. Sarcopenia is negatively associated with long-term outcomes in locally advanced rectal cancer.
    Choi MH; Oh SN; Lee IK; Oh ST; Won DD
    J Cachexia Sarcopenia Muscle; 2018 Feb; 9(1):53-59. PubMed ID: 28849630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can sarcopenia predict complete response after total neoadjuvant therapy in advanced rectal cancer?
    Yang XY; Hu Q
    J Surg Oncol; 2023 Jul; 128(1):179-180. PubMed ID: 37171111
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 13. Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study.
    Feng L; Liu Z; Li C; Li Z; Lou X; Shao L; Wang Y; Huang Y; Chen H; Pang X; Liu S; He F; Zheng J; Meng X; Xie P; Yang G; Ding Y; Wei M; Yun J; Hung MC; Zhou W; Wahl DR; Lan P; Tian J; Wan X
    Lancet Digit Health; 2022 Jan; 4(1):e8-e17. PubMed ID: 34952679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of sarcopenia on the outcome of patients with left-sided colon and rectal cancer after curative surgery.
    Li Q; An T; Wu J; Lu W; Wang Y; Li J; Yang L; Chen Y; Lin L; Yang Z
    BMC Cancer; 2023 Jul; 23(1):640. PubMed ID: 37430182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient's Skeletal Muscle Radiation Attenuation and Sarcopenic Obesity are Associated with Postoperative Morbidity after Neoadjuvant Chemoradiation and Resection for Rectal Cancer.
    Berkel AEM; Klaase JM; de Graaff F; Brusse-Keizer MGJ; Bongers BC; van Meeteren NLU
    Dig Surg; 2019; 36(5):376-383. PubMed ID: 29898443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized total neoadjuvant therapy versus chemotherapy during the 'wait period' versus standard chemoradiotherapy for locally advanced rectal cancer.
    Bedrikovetski S; Traeger L; Fitzsimmons T; Perry J; Vather R; Moore JW; Sammour T
    ANZ J Surg; 2023 May; 93(5):1267-1273. PubMed ID: 36573638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
    Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
    [No Abstract]   [Full Text] [Related]  

  • 18. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
    Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgery may not benefit patients with locally advanced rectal cancer who achieved clinical complete response following neoadjuvant chemoradiotherapy.
    Han Z; Li M; Chen J; Ji D; Zhan T; Peng Y; Xue W; Li Y; Cai Y; Sun Y; Wu Q; Du C; Gu J
    Asian J Surg; 2022 Jan; 45(1):97-104. PubMed ID: 33888366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.